We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .
A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia.
OBJECTIVES To compare the efficacy of paroxetine and imipramine prospect ively in patients with coexisting depression and dementia . METHODS An 8-week , double-blind , parallel group trial comparing paroxetine 20 - 40 mg/day with imipramine 50 - 100 mg/day in 198 patients aged 60 years or over with a Montgomery-Asberg Depression Rating Scale ( MADRS ) score > or = 20 and a Folstein mini-mental state evaluation score of 17 - 23 points after a 3- to 7-day placebo run-in period . RESULTS Both paroxetine and imipramine reduced the MADRS and the Clinical Global Impression ( CGI ) severity-of-illness and global improvement scores at weeks 2 , 4 , 8 and at endpoint , with no significant differences between treatment groups at any timepoint ( MADRS , p > or = 0.368 ; cgi , p > or = 0.286 ) . There was a statistically significant difference in favour of paroxetine at both the week 4 and week 8 timepoints ( analysis of variance , p < or = 0.049 ) in the Cornell scale for depression in dementia : at endpoint there was no significant difference between treatments ( p = 0.103 ) . Treatment-emergent adverse experiences were reported by 51.5 % ( 51/99 ) of patients treated with paroxetine and 50.5 % ( 50/99 ) of patients treated with imipramine .  Anticholinergic adverse experiences ( paroxetine 6.1 % ; imipramine 13.1 % ) and serious non-fatal adverse experiences ( paroxetine 4.0 % ; imipramine 8.1 % ) were reported by more patients in the imipramine group than in the paroxetine group . CONCLUSIONS Paroxetine and imipramine were both effective in the treatment of depression in elderly subjects with co-existing dementia , and no significant differences were detected between the groups . There were trends suggesting that paroxetine was better tolerated than imipramine in terms of anticholinergic adverse experiences and serious non-fatal adverse experiences
We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .